Investors brace for Tarsus earnings as Xdemvy doubts mount

Tarsus Pharmaceuticals is set to report Q1 results with analysts expecting a 30-cent loss per share on revenue of $153.12 million, but some estimates have been cut to as low as $141.3 million. The company’s XDEMVY franchise remains the key driver, with 2025 net sales above $450 million and 2026 guidance of $670-$700 million, though pricing pressure and prescription trends are raising investor caution. Shares are down 22% year-to-date even as Wall Street remains broadly bullish, with nine analysts rating the stock a buy and a mean target of $94.22.

Analysis

The market is pricing Tarsus as if Xdemvy is transitioning from launch acceleration to normalization, and that is the key inflection to watch. The base case is not a demand collapse; it’s a slowing growth rate that compresses the multiple because the stock had been discounting a much steeper adoption curve. The real near-term issue is that the company likely needs to prove both new patient conversion and repeat behavior simultaneously, which makes any disappointment on script data disproportionately painful.

The second-order risk is gross-to-net creep: in a category still expanding into a large untreated population, early commercial success often attracts more contracting pressure before durable brand equity is established. If discounting rises while growth decelerates even modestly, revenue can stay high but quality of revenue deteriorates, which is typically when biotech names de-rate fastest. The market will tolerate one weak quarter less than it will tolerate a guided-down year because the latter implies the launch is becoming harder, not just noisy.

IQV matters here as a read-through, but more as a sentiment/transmission channel than a direct revenue driver. If prescription trends are soft, the broader implication is that launch-stage biotech with concentrated product exposure will see investors become less forgiving on “large addressable market” narratives until they see proof of durable penetration. That can spill over into adjacent single-asset ophthalmology and specialty dermatology names that are trading on similar TAM-to-actuals gaps.

Contrarian setup: the consensus may be underestimating how much of the downside is already in the stock after a 22% YTD drawdown. If management confirms guidance or only modestly misses while reaffirming peak-sales ambition, the squeeze risk is real because positioning is likely defensive and analyst estimates have already been cut. The asymmetry is now less about whether the story is great, and more about whether the company can avoid validating the bear case that launch momentum is already peaking.

Key Decisions for Investors

• TARS: avoid initiating fresh longs into the print; wait for the reaction. If revenue is within ~5% of guide and gross-to-net is stable, consider a tactical long on the post-earnings selloff for a 2-4 week mean reversion trade with a tight stop below the day-two low.
• TARS: if results show sub-guide sales and any gross-to-net expansion, short the bounce or buy puts into the first relief rally. Risk/reward improves because the market has less patience for a second consecutive quality-of-revenue miss.
• Pair trade: short TARS vs long IQV for 1-3 months. If script data softens, TARS should underperform while IQV benefits from broader launch/claims analytics demand and lower single-product idiosyncratic risk.
• For biotech exposure, rotate away from single-product launch names with concentrated revenue reliance until post-earnings visibility improves. Prefer diversified commercial-stage names where one miss does not reset the valuation framework.